Efficacy and Safety of Hetrombopag for Thrombocytopenia in Patients with Advanced Solid Tumors: A Retrospective Study

Table 3

Proportion of patients recovered to ≥75 × 109/L in 14 days by characteristics (n, %).

Variable	Number of patients (n)	PLT recovered to ≥75 × 109/L on (14 ± 2) days of hetrombopag treatment		χ^2	value
		Yes n (%)	No n (%)
Age
>60 years	36	29 (80.6%)	7 (19.4%)	0.074	0.785
≤60 years	24	20 (83.3%)	4 (16.7%)
Gender
Male	34	26 (76.5%)	8 (23.5%)	1.415	0.234
Female	26	23 (88.5%)	3 (11.5%)
Baseline platelet count
50 × 10^9/L∼75 × 10^9/L (grade 2 thrombocytopenia)	37	35 (94.6%)	2 (5.4%)	14.886	0.001
25 × 10^9/L∼50 × 10^9/L (grade 3 thrombocytopenia)	17	12 (70.6%)	5 (29.4%)
<25 × 10^9/L (grade 4 thrombocytopenia)	6	2 (33.3%)	4 (66.7%)
Antitumor treatment regimen
Chemotherapy only	13	13 (100.0%)	0 (0.0%)	4.516	0.211
Targeted/targeted + chemotherapy only	12	10 (83.3%)	2 (16.7%)
Immune/immune + chemotherapy only	17	12 (70.6%)	5 (29.4%)
Targeting + immunization/targeting + immunization + chemotherapy	18	14 (77.8%)	4 (22.2%)
Prior platelet increasing therapy
rhTPO	36	28 (77.8%)	8 (22.2%)	1.410	0.494
TPO-RA (avatrapopag, eltrombopag)	4	3 (75.0%)	1 (25.0%)
None	20	18 (90.0%)	2 (10.0%)
Hetrombopag therapeutic dose
2.5 mg	11	10 (90.9%)	1 (9.1%)	0.786	0.381
5 mg	49	39 (79.6%)	10 (20.4%)

rhTPO, recombinant human thrombopoietin; TPO-RA; thrombopoietin receptor agonist.